

Presentación Pública del Proyecto EUROFANCOLEN

“Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector the FANCA gene: A Coordinated International Action”



European Commission. Contract Number: 305421

LUGAR: CIEMAT (Salón de Actos).

Avenida Complutense 40. 28040 Madrid

Fecha: Lunes 28 de Enero 2013 a las 15,00 horas.

AGENDA:

15:15-15:30h: Bienvenida/Wellcome: *Ramón Gavela, Director General Adjunto. CIEMAT.*

15:30-16:00h: Past, present and future in the therapy of Fanconi anemia. *Eliane Gluckman. Saint Louis Hospital. Paris*

16:00-16:30h: Advances of hematopoietic gene therapy trials in France (X1-SCID; B-Thalassemia). *Marina Cavazzana. Necker Hospital. Paris*

16:30-17:00h: Advances of hematopoietic gene therapy trials in UK (ADA; X1-SCID). *Adrian Thrasher. University Colledge. London*

17:00-17:30h: The mission of GENETHON in gene therapy of rare diseases: *Fulvio Mavilio. Scientific Director of Genethon. Evry.*

17:30- 18:00h: EUROFANCOLEN: Towards the cure of the bone marrow failure of Fanconi anemia patients with lentiviral vectors. *Juan Bueren. Ciemat/Ciberer. Madrid*